作者
Eric M. Merten,John D. Sears,Tina M. Leisner,P. Brian Hardy,Anirban Ghoshal,Mohammad Anwar Hossain,Kesatebrhan Haile Asressu,Peter J. Brown,Edwin G. Tse,Michael A. Stashko,Kelin Li,Jacqueline L. Norris‐Drouin,Laura E. Herring,Angie L. Mordant,Thomas S. Webb,Christine A. Mills,Natalie K. Barker,Zachary J. Streblow,Sumera Perveen,C.H. Arrowsmith,R.M. Counago,Jamie J. Arnold,Craig E. Cameron,Daniel N. Streblow,Nathaniel J. Moorman,Mark T. Heise,Timothy M. Willson,Konstantin Popov,Kenneth H. Pearce
摘要
Chikungunya virus (CHIKV) is a mosquito-borne alphavirus that has been responsible for numerous large-scale outbreaks in the last twenty years. Currently, there are no FDA-approved therapeutics for any alphavirus infection. CHIKV nonstructural protein 2 (nsP2), which contains a cysteine protease domain, is essential for viral replication, making it an attractive target for a drug discovery campaign. Here, we optimized a CHIKV nsP2 protease (nsP2pro) biochemical assay for the screening of a 6,120-compound cysteine-directed covalent fragment library. Using a 50% inhibition threshold, we identified 153 hits (2.5% hit rate). In dose-response follow-up, RA-0002034, a covalent fragment that contains a vinyl sulfone warhead, inhibited CHIKV nsP2pro with an IC